Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3090106- SQ · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3090106 (Healthy) | EXPERIMENTAL | Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ). |
| Placebo (Healthy) | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo matching LY3090106 SQ. |
| LY3090106 (RA) | EXPERIMENTAL | Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV). |
| Placebo (RA) | PLACEBO_COMPARATOR | Participants with RA will receive a single dose of placebo matching LY3090106 SQ. |
| Name | Type | Description |
|---|---|---|
| LY3090106 - SQ | BIOLOGICAL | Administered SQ. |
| LY3090106 - IV | BIOLOGICAL | Administered IV. |
| Placebo - SQ | BIOLOGICAL | Administered SQ. |
Inclusion Criteria for Healthy Participants: * Males or non-pregnant females age 18 to 65 years * Body Mass Index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2) Inclusion Criteria for Participants for RA: * Diagnosis of at least mildly active adult-onset RA * Positive anti-citrullina...
Top 20 of 31 competitors
LY3090106- SQ is an investigational monoclonal antibody developed by Eli Lilly and Company for rheumatoid arthritis. It has been studied in a Phase 1 clinical trial that enrolled 43 participants, including healthy volunteers and people with rheumatoid arthritis. The drug is not approved and remains in clinical development.
LY3090106- SQ is being evaluated as a treatment for rheumatoid arthritis, an autoimmune condition. It was tested in a Phase 1 trial that included participants with rheumatoid arthritis alongside healthy volunteers. The study is complete, but the drug has not been approved for any use.
LY3090106- SQ is made by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the developer responsible for the clinical program studying this monoclonal antibody in rheumatoid arthritis.
LY3090106- SQ is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug is investigational and has not received FDA approval for rheumatoid arthritis or any other indication.
LY3090106- SQ has been studied in one completed Phase 1 trial, NCT01925157, titled A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA). The trial enrolled 43 participants across Bulgaria, Moldova, Poland, and Romania and was randomized, double-blind, and placebo-controlled.
Yes, LY3090106- SQ and LY3090106 - SQ refer to the same investigational monoclonal antibody developed by Eli Lilly and Company for rheumatoid arthritis. The only difference is spacing in the name, and both point to the same Phase 1 clinical program.